# Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

> **NCT00080236** · PHASE2 · COMPLETED · sponsor: **Conatus Pharmaceuticals Inc.** · enrollment: 99 (actual)

## Conditions studied

- Liver Transplantation
- Hepatitis
- Cholestasis
- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** IDN-6556
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00080236
- **Lead sponsor:** Conatus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2012-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080236, "Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00080236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*